Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen-Cilag S.p.A.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have a first or confirmed diagnosis of Spondyloarthritis (SpA) according to Assessment of Spondyloarthritis classification (ASAS) criteria
Participants must be naïve to conventional, targeted and biological Disease modifying anti-rheumatic drugs (DMARDs) treatment
Participants must understand the purpose of the study
Participants must sign a participation agreement/ Informed Consent Form (ICF) allowing data collection and source data verification in accordance with local requirements
You may not be if
Participants who already started conventional, targeted and biological DMARDs treatment for SpA
Participants who participate to an investigational study in the last 30 days
Participants unwilling or unable to participate in long-term, 24 months, data collection
Participants unwilling or unable to fill in the Participant-reported outcome (PRO) foreseen by the protocol
Participants unwilling or unable to sign the informed consent to the study
Clareo Health | A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs
